BofA Maintains an Underperform Rating on Hims & Hers Health, Inc. (HIMS)

TheFly reported connected January 8, 2026, that BofA reduced the terms people for Hims & Hers Health, Inc. (NYSE:HIMS) to $29 from $32. It retained an Underperform standing connected the stock. The steadfast claims that the statement expectations for income and EBITDA margins successful 2026 are excessively high. It notes that 2026 volition beryllium Hims & Hers’ “big concern year” and that projections for an summation successful EBITDA borderline look excessively optimistic. BofA expects antagonistic net revisions successful the upcoming months and risks of downside to 2026 gross and EBITDA margins.

Citi reported connected January 5, 2026, that the corp was erstwhile much near disconnected of Novo Nordisk’s spouse database for the Wegovy value nonaccomplishment pill’s U.S. launch. It besides includes CVS Health, Costco, LifeMD, and GoodRx. This exclusion is perchance owed to differences betwixt Novo and the company’s compounded semaglutide strategy. In 2026, Citi forecasts that the Wegovy motorboat volition enactment unit connected Hims & Hers Health, Inc. (NYSE:HIMS) GLP-1 business. The steadfast remains to person a $30 terms people and a Sell rating. In the premarket, the banal was trading astatine $33.85, up $0.44.

Hims & Hers Health, Inc. (NYSE:HIMS) is 1 of the apical telehealth firms successful the United States.

While we admit the imaginable of HIMS arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.